Fundraising Fox
Viome Life Sciences
Bellevue, US · Founded 2016 · 96 employees on LinkedIn · 13 known investors
Find your way into Viome Life Sciences
Each arrow is one introduction. Sign up to fill in the first one.
Ask Katie Biber to introduce you to Guruduth Banavar
You →Katie · together at Rumble.com →Guruduth
Ask Jamie Chen to introduce you to Shannon Pappas
You →Jamie · together at Tot Squad →Shannon
Ask Sam Okafor to introduce you to Helene Vollbracht
You →Sam · together at Uber →Helene
- Naveen Jain337 people can intro you
- Michael Bass233 people can intro you
- DEEPAK SAVADATTI85 people can intro you
Sign up to find every way you can get introduced to Viome Life Sciences
- Your email: who you already know at Viome Life Sciences, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Viome Life Sciences team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Viome offers at-home tests that analyze the gut and oral microbiome plus cellular blood samples using mRNA/metatranscriptomic sequencing, returning 70+ health scores (including biological age and inflammation) and personalized food and supplement recommendations. The direct-to-consumer service, analyzed in a CLIA-certified lab, is aimed at individuals seeking insights into digestion, metabolism, and overall wellness.
Also known as Viome Life Sciences · Viome Life Sciences, Inc.
Founders & leadership
Viome Life Sciences was founded in 2016 by Naveen Jain, Guruduth Banavar, and Momo Vuyisich.
Board
Investors · 13
How we know: Bold Capital Partners's portfolio page · a partner's Signal profile · research · fiercehealthcare.com · Not right? Tell us
How we know: SquareOne Capital's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · prnewswire.com · Not right? Tell us
How we know: research · geekwire.com · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Also in the syndicate · 6
Reported raises · per SEC filings
Form D private placements$161.5M disclosed across 6 of 8 rounds · 2017–2024
▶$25.4MraisedAug 2024 · 44 investors · OtherRule 506(b)
- Naveen K JainExecutive Officer, Director
- Christopher KitzeDirector
- William A. OwensDirector
- Erik AndersonDirector
- Alex MorganDirector
- Teymour Boutros-GhaliDirector
- Offering amount
- $30M
- Amount sold
- $25.4M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$67MraisedOct 2022 · 34 investors · OtherRule 506(b)
- GREGORY J. MOOREDirector
- Erik AndersonDirector
- Christopher KitzeDirector
- Naveen JainExecutive Officer, Director
- William A. OwensDirector
- Steven W. SansomDirector
- EIICHIRO KIMURADirector
- Offering amount
- $96.9M
- Amount sold
- $67M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedFeb 2021 · 2 investors · OtherRule 506(b)
- George MontgomeryDirector
- William A. OwensDirector
- Naveen JainExecutive Officer, Director
- Christopher KitzeDirector
- Offering amount
- $12.5M
- Amount sold
- $3M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$36.5MraisedNov 2019 · 18 investors · OtherRule 506(b)
- Naveen JainExecutive Officer, Director
- George MontgomeryDirector
- Deepak SavadattiExecutive Officer
- Christopher KitzeDirector
- Offering amount
- $106M
- Amount sold
- $36.5M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$14.6MraisedAug 2018 · 6 investors · OtherRule 506(b)
- NAVEEN K JAINExecutive Officer, Director
- DEEPAK SAVADATTIExecutive Officer
- Offering amount
- $21M
- Amount sold
- $14.6M
- Minimum investment
- $100K
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$15MraisedJul 2017 · 2 investors · OtherRule 506(b)
- DEEPAK SAVADATTIExecutive Officer
- NAVEEN K JAINExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $15M
- Minimum investment
- $500K
- First sale
- Jul 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Viome Life Sciences is a Bellevue, Washington-based preventative health and longevity company that sells at-home test kits analyzing stool, saliva and blood samples. Rather than sequencing DNA, the company uses proprietary RNA sequencing (gene expression) methods combined with AI to assess microbial activity and epigenetic biomarkers, and translates the results into personalized nutrition guidance, custom supplement formulas, gut biotic blends and oral biotic lozenges. Samples are processed in a CLIA-certified laboratory, and the company states it analyzes microbial activity across more than 400 biological pathways.
Consumer offerings include a Gut Intelligence Test and a Full Body Intelligence Test, the latter a three-in-one test returning 70 health scores and more than 370 personalized food recommendations, with plans updated approximately every six months as customers retest. Health areas addressed include gut health, metabolic health and weight, brain health and mood, women's health, and healthy aging and longevity. Viome has also expanded into oral health with an Oral Health Intelligence Test for consumers and Oral Health Pro with CancerDetect for dental professionals, and into diagnostics with CancerDetect, a test for oral and throat cancer that received FDA breakthrough device designation and which the company reports at 90% sensitivity and 95% specificity. Additional diagnostics under consideration include tests for irritable bowel syndrome and inflammatory bowel disease.
Founding story
Founder and CEO Naveen Jain launched Viome in 2016 as a spin-off from Blue Dot; it is his seventh venture, following InfoSpace, public records firm Intelius and lunar lander company Moon Express. Jain has said the company was built on the premise that DNA does not change when chronic disease develops, so the relevant signal is RNA and gene expression.
Business model
Direct-to-consumer sale of at-home test kits paired with recurring, personalized health products (custom supplements, gut biotic blends, oral biotic lozenges) and subscription-style nutrition plans, with distribution extended into national retail. The company states test kits are purchased nearly at cost by consumers, and that it does not sell patient data but uses it to develop future products.
Product and subscription revenue: full body health packages were priced at $199 per month including nutritional health plans, and the gut-only test was sold at $149 through CVS stores. A professional channel exists via Oral Health Pro with CancerDetect for dental practices.
Traction
Over 500,000 users empowered as of 2023 and over 50 million microbiome insights delivered per the company website; a gene expression database of more than 600,000 samples; retail distribution in 200 CVS stores from August 2023; and roughly $200 million raised in total as of September 2024.
Latest developments
In September 2024 Viome announced a $25 million Series D from existing investors including Khosla Ventures, Bold Capital, WRG Ventures and Marc Benioff, and appointed Kal Raman as COO to scale its diagnostics business, with interest in developing tests for IBS and IBD. Its consumer line is currently marketed around the Gut Intelligence and Full Body Intelligence tests.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned as a longevity and preventative healthcare company in the consumer microbiome testing market, differentiating on RNA/gene-expression analysis versus DNA-based competitors. The company reports having served over half a million users and delivered over 50 million microbiome insights. The size of the microbiome health market is estimated inconsistently across sources, though it is generally regarded as growing.
Emphasis on RNA and gene expression rather than DNA-based testing, measurement of microbial metabolic output rather than species composition alone, a large proprietary gene expression database, integration of diagnostics (FDA breakthrough-designated CancerDetect) with consumer nutrition products, and manufacture of individualized supplement and biotic formulations.
Technology
Proprietary RNA sequencing (metatranscriptomic/gene expression) analysis of stool, saliva and blood samples processed in a CLIA-certified lab, coupled with AI and algorithms trained on what the company describes as the world's largest gene expression data pool of over 600,000 samples. The platform measures what microbes produce rather than only which organisms are present, mapping microbial activity across 400+ biological pathways, and matches RNA findings to biomarkers linked to cancer for its CancerDetect diagnostic.
Go-to-market
Online direct-to-consumer sales through viome.com with free US shipping, complemented by retail distribution — the Gut Intelligence Test launched into 200 CVS locations nationwide in August 2023, described as the first gut test sold in the chain both online and in-store. Earlier go-to-market efforts included a deal with Nordstrom to sell at-home stool sample kits and the use of Paris Hilton as an investor and brand ambassador.
Consumers seeking personalized nutrition and preventative health insights across gut, metabolic, cognitive, oral, women's and longevity-related health concerns; dental professionals for the oral health/CancerDetect product line.
Geography
Headquartered in Bellevue, Washington, with US-focused direct-to-consumer sales (free shipping on US orders) and nationwide US retail distribution through CVS.
History
Viome was launched in 2016 by Naveen Jain and was spun off from Blue Dot. It raised a $67 million Series C announced in October 2022 to expand research and oral microbiome testing, then closed an $86.5 million oversubscribed Series C extension in August 2023 alongside the CVS retail launch. In November 2023 it acquired Naring Health, including DiscernDX and Foodome. In September 2024 it raised a $25 million Series D and hired Kal Raman, a former Amazon senior vice president and Samsung chief digital officer, as chief operating officer to expand its diagnostics division.
Risks & controversies
Some scientists and researchers remain wary of microbiome kit companies generally, citing a lack of scientific rigor and regulation; Viome has a handful of peer-reviewed studies, and some researchers have questioned its methodology. Founder Naveen Jain previously led InfoSpace, which crashed in the dot-com bubble amid lawsuits.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through Viome Life Sciences went on to found or lead other companies.
Timeline · 7
launches, deals, and filingsViome announced a $25 million Series D round from existing investors including Khosla Ventures, Bold Capital, WRG Ventures and Marc Benioff, bringing total funding to $200 million.
$25M source ↗
Viome hired Kal Raman, previously an Amazon senior vice president and Samsung chief digital officer, as COO to help scale its diagnostics division.
Viome acquired digital health and wellness company Naring Health, including DiscernDX and Foodome, adding patents and IP in multi-omics, proteomics and food science to its personalized nutrition offering.
Viome Life Sciences announced the close of an $86.5 million oversubscribed Series C round, an extension of the $67 million Series C announced in October 2022, bringing total funding to $175 million to support R&D and retail expansion.
$86.5M source ↗
Viome's Gut Intelligence Test became available online and in-store at 200 CVS locations nationwide, described as the first gut test sold in the national retail chain.
Viome announced its Oral Health Solutions, applying RNA sequencing technology to oral health, including the Oral Health Intelligence Test for consumers and Oral Health Pro with CancerDetect for dental professionals.
Viome's at-home test for biomarkers of early-stage oral and throat cancers received breakthrough device designation from the U.S. Food and Drug Administration.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Viomeviome.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Viome Life Sciences do?
- Viome sells at-home RNA-sequencing microbiome tests that generate personalized food, supplement and biotic recommendations.
- Who founded Viome Life Sciences?
- Viome Life Sciences was founded by Naveen Jain, Guruduth Banavar, Momo Vuyisich in 2016.
- Who are Viome Life Sciences's investors?
- Viome Life Sciences's investors include Bold Capital Partners, Eastward Capital Partners, SquareOne Capital, WestRiver Group, Khosla Ventures, Marc Benioff, Milltrust International Group.
- How much funding has Viome Life Sciences raised?
- Viome Life Sciences has disclosed $161.5M raised across 6 of its 8 known rounds.
- Where is Viome Life Sciences headquartered?
- Viome Life Sciences is headquartered in Bellevue, US.